(ZIMV) ZimVie - Ratings and Ratios
Spine Implants, Dental Implants
ZIMV EPS (Earnings per Share)
ZIMV Revenue
Description: ZIMV ZimVie
ZimVie Inc. is a dental technology company that develops, manufactures, and markets products and solutions for dental tooth replacement and restoration procedures globally. The companys product portfolio includes dental implant systems, biomaterials, digital dentistry solutions, and patient-specific restorative solutions.
Key products and services offered by ZimVie include bone grafts, barrier membranes, and collagen wound care products, as well as virtual treatment planning services and guided surgery solutions. The company sells its products to a diverse customer base, including oral surgeons, dental specialists, general dentists, and dental laboratories, through various channels such as sales representatives, independent sales agents, and distributors.
From a financial perspective, ZimVies market capitalization is approximately $251.29 million, with a forward price-to-earnings ratio of 11.14. The companys return on equity is currently negative, indicating a need for improvement in profitability. To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating expense ratio can be monitored. Additionally, metrics like dental implant market share, customer satisfaction ratings, and product innovation pipeline can provide insights into the companys competitive position and future prospects.
Some relevant KPIs to track for ZimVie include: - Revenue growth rate: to assess the companys ability to expand its customer base and increase sales. - Gross margin: to evaluate the companys pricing power and production efficiency. - Research and development (R&D) expense as a percentage of revenue: to gauge the companys commitment to innovation and new product development. - Customer acquisition cost and customer retention rate: to assess the companys sales and marketing effectiveness. - Product mix and average selling price (ASP) trends: to understand the companys pricing strategy and product portfolio optimization.
ZIMV Stock Overview
| Market Cap in USD | 533m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2022-03-01 |
ZIMV Stock Ratings
| Growth Rating | 26.3% |
| Fundamental | 41.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -5.01% |
| Analyst Rating | 3.25 of 5 |
ZIMV Dividends
Currently no dividends paidZIMV Growth Ratios
| Growth Correlation 3m | 87.4% |
| Growth Correlation 12m | -12.9% |
| Growth Correlation 5y | -6.8% |
| CAGR 5y | 16.17% |
| CAGR/Max DD 3y | 0.26 |
| CAGR/Mean DD 3y | 0.65 |
| Sharpe Ratio 12m | -0.03 |
| Alpha | 0.00 |
| Beta | 0.832 |
| Volatility | 45.99% |
| Current Volume | 239k |
| Average Volume 20d | 313.5k |
| Stop Loss | 18.3 (-3.1%) |
| Signal | -0.28 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-19.5m TTM) > 0 and > 6% of Revenue (6% = 26.6m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -2.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 33.96% (prev 24.09%; Δ 9.87pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 12.0m > Net Income -19.5m (YES >=105%, WARN >=100%) |
| Net Debt (164.4m) to EBITDA (42.9m) ratio: 3.83 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (28.0m) change vs 12m ago 2.17% (target <= -2.0% for YES) |
| Gross Margin 65.31% (prev 72.29%; Δ -6.98pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.29% (prev 69.76%; Δ -12.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.49 (EBITDA TTM 42.9m / Interest Expense TTM 16.8m) >= 6 (WARN >= 3) |
Altman Z'' -2.27
| (A) 0.20 = (Total Current Assets 260.2m - Total Current Liabilities 109.6m) / Total Assets 758.2m |
| (B) -0.62 = Retained Earnings (Balance) -472.1m / Total Assets 758.2m |
| (C) 0.01 = EBIT TTM 8.22m / Avg Total Assets 774.0m |
| (D) -1.54 = Book Value of Equity -532.7m / Total Liabilities 345.4m |
| Total Rating: -2.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.11
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield 0.82% = 0.41 |
| 3. FCF Margin 1.27% = 0.32 |
| 4. Debt/Equity 0.54 = 2.36 |
| 5. Debt/Ebitda 5.23 = -2.50 |
| 6. ROIC - WACC (= 1.65)% = 2.06 |
| 7. RoE -4.88% = -0.81 |
| 8. Rev. Trend -86.35% = -6.48 |
| 9. EPS Trend -4.99% = -0.25 |
What is the price of ZIMV shares?
Over the past week, the price has changed by +0.16%, over one month by -0.32%, over three months by +105.55% and over the past year by +12.78%.
Is ZimVie a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZIMV is around 16.69 USD . This means that ZIMV is currently overvalued and has a potential downside of -11.65%.
Is ZIMV a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the ZIMV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19 | 0.6% |
| Analysts Target Price | 19 | 0.6% |
| ValueRay Target Price | 18.7 | -1% |
Last update: 2025-09-13 04:44
ZIMV Fundamental Data Overview
CCE Cash And Equivalents = 70.2m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 22.1239
P/S = 1.2012
P/B = 1.2889
Beta = 2.075
Revenue TTM = 443.4m USD
EBIT TTM = 8.22m USD
EBITDA TTM = 42.9m USD
Long Term Debt = 220.8m USD (from longTermDebt, last quarter)
Short Term Debt = 3.69m USD (from shortTermDebt, last quarter)
Debt = 224.5m USD (Calculated: Short Term 3.69m + Long Term 220.8m)
Net Debt = 164.4m USD (from netDebt column, last quarter)
Enterprise Value = 686.9m USD (532.6m + Debt 224.5m - CCE 70.2m)
Interest Coverage Ratio = 0.49 (Ebit TTM 8.22m / Interest Expense TTM 16.8m)
FCF Yield = 0.82% (FCF TTM 5.62m / Enterprise Value 686.9m)
FCF Margin = 1.27% (FCF TTM 5.62m / Revenue TTM 443.4m)
Net Margin = -4.39% (Net Income TTM -19.5m / Revenue TTM 443.4m)
Gross Margin = 65.31% ((Revenue TTM 443.4m - Cost of Revenue TTM 153.8m) / Revenue TTM)
Tobins Q-Ratio = -1.29 (set to none) (Enterprise Value 686.9m / Book Value Of Equity -532.7m)
Interest Expense / Debt = 1.71% (Interest Expense 3.84m / Debt 224.5m)
Taxrate = 1541 % (set to none) (4.12m / 267.0k)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.37 (Total Current Assets 260.2m / Total Current Liabilities 109.6m)
Debt / Equity = 0.54 (Debt 224.5m / last Quarter total Stockholder Equity 412.8m)
Debt / EBITDA = 5.23 (Net Debt 164.4m / EBITDA 42.9m)
Debt / FCF = 39.97 (Debt 224.5m / FCF TTM 5.62m)
Total Stockholder Equity = 399.1m (last 4 quarters mean)
RoA = -2.57% (Net Income -19.5m, Total Assets 758.2m )
RoE = -4.88% (Net Income TTM -19.5m / Total Stockholder Equity 399.1m)
RoCE = 1.33% (Ebit 8.22m / (Equity 399.1m + L.T.Debt 220.8m))
RoIC = 1.65% (Ebit 8.22m / (Assets 758.2m - Current Assets 260.2m))
WACC = unknown (E(532.6m)/V(757.1m) * Re(9.08%)) + (D(224.5m)/V(757.1m) * Rd(1.71%) * (1-Tc(none)))
Shares Correlation 3-Years: 90.91 | Cagr: 0.62%
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 65.91% ; FCFE base≈13.3m ; Y1≈8.73m ; Y5≈3.99m
Fair Price DCF = 2.36 (DCF Value 66.5m / Shares Outstanding 28.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -4.99 | EPS CAGR: -20.58% | SUE: 0.43 | # QB: 0
Revenue Correlation: -86.35 | Revenue CAGR: -19.88% | SUE: N/A | # QB: None
Additional Sources for ZIMV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle